| 1. |
|
| 2. |
|
| 3. |
Smith JR, Ashander LM, Arruda SL, et al. Pathogenesis of ocular toxoplasmosis[J/OL]. Prog Retin Eye Res, 2021, 81: 100882[2020-07-24]. https://pubmed.ncbi.nlm.nih.gov/32717377/. DOI: 10.1016/j.preteyeres.2020.100882.
|
| 4. |
|
| 5. |
陶勇. 眼內液病原學檢測的研究進展[J]. 中華眼科雜志, 2018, 54(7): 551-556. DOI: 10.3760/cma.j.issn.0412-4081.2018.07.019.Tao Y. Research on examination of intraocular fluid for diagnosis of infectious ocular diseases[J]. Chin J Ophthalmol, 2018, 54(7): 551- 556. DOI: 10.3760/cma.j.issn.0412-4081.2018.07.019.
|
| 6. |
Garweg JG, Pleyer U. Treatment strategy in human ocular toxoplasmosis: why antibiotics have failed[J/OL]. J Clin Med, 2021, 10(5): 1090[2021-03-05]. https://pubmed.ncbi.nlm.nih.gov/33807871/. DOI: 10.3390/jcm10051090.
|
| 7. |
邱燕華, 董朕, 張吉麗, 等. 弓形蟲病的治療研究進展[J]. 中國動物 傳染病學報, 2023, 31(4): 213-222.Qiu YH, Dong Z, Zhagn JL, et al. Advances in the treatment of toxoplasmosis[J]. Chinese Journal of Animal Infectious Diseases, 2023, 31(4): 213-222.
|
| 8. |
Dunay IR, Gajurel K, Dhakal R, et al. Treatment of toxoplasmosis: historical perspective, animal models, and current clinical practice[J/OL]. Clin Microbiol Rev, 2018, 31(4): e57-e67[2018-09-12]. https://pubmed.ncbi.nlm.nih.gov/30209035/. DOI: 10.1128/CMR.00057-17.
|
| 9. |
Fernandes Felix JP, Cavalcanti Lira RP, Grupenmacher AT, et al. Long-term results of trimethoprim-sulfamethoxazole versus placebo to reduce the risk of recurrent Toxoplasma gondii retinochoroiditis[J]. Am J Ophthalmol, 2020, 213: 195-202. DOI: 10.1016/j.ajo.2019.12.025.
|
